Studies have confirmed that liquid droplets formed by ubiquilin-2 (UBQLN2) facilitate the aggregation and fibril formation of α-synuclein protein. Researchers also discovered a compound that interacts with UBQLN2, preventing its self-association and liquid droplet formation, which may lead to new treatments for neurodegenerative diseases.
SourceJuntendo University Research Promotion Center·JournalThe EMBO Journal·TypeExperimental study·DateNov 26, 2025
Researchers from Tokyo Medical and Dental University demonstrate a proof of concept for antisense nucleic acid therapy to prevent the spread of α-synuclein pathologies in synucleinopathies. The treatment, involving antisense oligonucleotides, effectively reduces Lewy pathology-like neuronal inclusion by over 90%.
SourceTokyo Medical and Dental University·JournalActa Neuropathologica Communications·DateJul 25, 2024
Researchers at Tokyo Medical and Dental University found that mutant α-synuclein protein propagates through the brain's lymphatic system in its monomeric state before aggregating, shedding light on Parkinson's disease progression. The study suggests targeting early events may limit disease progression.
SourceTokyo Medical and Dental University·JournalCell Reports·DateSep 7, 2023
A new study reveals that aggregates of the protein alpha-synuclein spread in the brains of people with Parkinson's disease through a cellular waste-ejection process called lysosomal exocytosis. This process can lead to the deaths of neurons and ultimately result in the characteristic symptoms of the disease.
SourceWeill Cornell Medicine·JournalNature Communications·DateSep 20, 2022
Kestrel 3000 Pocket Weather Meter
Kestrel 3000 Pocket Weather Meter measures wind, temperature, and humidity in real time for site assessments, aviation checks, and safety briefings.
Researchers from Johns Hopkins Medicine and Dana Farber Cancer Institute found that irisin reduces levels of a protein linked to Parkinson's disease and halts movement problems in mice. Irisin also speeds up the transport and degradation of alpha synuclein via fluid-filled sacs called lysosomes in brain cells.
SourceJohns Hopkins Medicine·JournalProceedings of the National Academy of Sciences·DateSep 12, 2022
Researchers at Johns Hopkins Medicine identified a chemical compound that stops the final events in the pathway linked to brain cell death in Parkinson’s disease. The compound, PAANIB-1, blocks the protein parthanatos without affecting its other critical activities, potentially halting neurodegenerative progression.
SourceJohns Hopkins Medicine·JournalCell·DateJun 1, 2022
Researchers at the University of Bath have optimised a peptide that prevents alpha-synuclein misfolding, a key feature of Parkinson's disease. The new molecule, 4654W(N6A), has shown significant promise in lab experiments and could lead to the development of a disease-modifying treatment.
SourceUniversity of Bath·JournalJournal of Molecular Biology·TypeExperimental study·DateDec 9, 2021
Researchers will investigate hidden signs of brain damage in REM behavior disorder, aiming to identify biomarkers that predict impending neurological disease. The goal is to delay the onset or prevent dementia or Parkinsonism through clinical trials.
Biologist Aleksey Belikov proposes that rapid progression of age-related diseases results from vicious cycles triggered by biochemical reactions. The study highlights the importance of interrupting these cycles in preventing disease progression.
SourceMoscow Institute of Physics and Technology·JournalAgeing Research Reviews·DateFeb 11, 2019
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
A study published in Science identifies Parthanatos as a key driver of nerve cell degradation in Parkinson's disease. The researchers found that blocking a protein called PARP1 can rescue cells from death, suggesting new targets for drugs to interrupt the disease progression.
SourceJohns Hopkins Medicine·JournalScience·DateNov 1, 2018
Scientists have long debated the structure of alpha synuclein, a protein associated with Parkinson's. A new study models its structure, finding that it can rapidly switch between different conformations. The researchers suggest that stabilizing an ordered structure could prevent aggregation and offer a new drug-design strategy.
SourceMassachusetts Institute of Technology·JournalJournal of the American Chemical Society·DateApr 1, 2013
Brandeis researchers have produced and determined the structure of alpha-synuclein, a key protein linked to Parkinson's disease. The findings may lead to the development of new treatments by stabilizing the protein.
SourceBrandeis University·JournalProceedings of the National Academy of Sciences·DateOct 23, 2011
Researchers have found elevated levels of gamma-synuclein in depressed animals and humans, highlighting its role in regulating neurotransmitters. The study may provide new therapeutic targets for treating depression, which currently has limited effective treatments.
Research suggests that variations in the alpha synuclein gene contribute to alcohol craving in certain individuals. The study found eight SNPs associated with alcohol craving, but not with dependence, indicating a possible subtype of alcoholics influenced by this genetic factor.
SourceAlcoholism: Clinical & Experimental Research·DateMar 26, 2007
Meta Quest 3 512GB
Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.
Researchers have discovered that synuclein plays a crucial role in communication between neurons, potentially shedding light on the mechanisms underlying Parkinson's and Alzheimer's diseases. The study provides strong evidence that synucleins control the release of neurotransmitters from nerve cells.